These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 23129068)
1. Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease. Oyeku SO; Driscoll MC; Cohen HW; Trachtman R; Pashankar F; Mullen C; Giardina PJ; Velazco N; Racine AD; Green NS Pediatr Blood Cancer; 2013 Apr; 60(4):653-8. PubMed ID: 23129068 [TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea in children with sickle cell disease in a resource-poor setting: Monitoring and effects of therapy. A practical perspective. Nnebe-Agumadu U; Adebayo I; Erigbuem I; James E; Kumode E; Nnodu O; Adekile A Pediatr Blood Cancer; 2021 Jun; 68(6):e28969. PubMed ID: 33788390 [TBL] [Abstract][Full Text] [Related]
3. Do difficulties in swallowing medication impede the use of hydroxyurea in children? Bekele E; Thornburg CD; Brandow AM; Sharma M; Smaldone AM; Jin Z; Green NS Pediatr Blood Cancer; 2014 Sep; 61(9):1536-9. PubMed ID: 24753149 [TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea for the treatment of sickle cell disease. Segal JB; Strouse JJ; Beach MC; Haywood C; Witkop C; Park H; Wilson RF; Bass EB; Lanzkron S Evid Rep Technol Assess (Full Rep); 2008 Mar; (165):1-95. PubMed ID: 18457478 [TBL] [Abstract][Full Text] [Related]
5. Understanding patient-related barriers to hydroxyurea use among adolescent and adult patients with sickle cell disease in Mulago and Kiruddu hospitals, Uganda, a qualitative study. Namaganda P; Nantume P; Mubiru KR; Twimukye A; Wiltshire CS BMC Health Serv Res; 2024 May; 24(1):666. PubMed ID: 38802815 [TBL] [Abstract][Full Text] [Related]
6. Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria. Adeyemo TA; Diaku-Akinwunmi IN; Ojewunmi OO; Bolarinwa AB; Adekile AD Hemoglobin; 2019 May; 43(3):188-192. PubMed ID: 31462098 [TBL] [Abstract][Full Text] [Related]
7. Perception to hydroxyurea therapy in patients with sickle cell disease: Report from 3 centers. Korubo KI; Onodingene NM; Okoye HC; Omunakwe HE Ann Afr Med; 2021; 20(2):127-131. PubMed ID: 34213480 [TBL] [Abstract][Full Text] [Related]
8. Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease. Smaldone A; Findley S; Bakken S; Matiz LA; Rosenthal SL; Jia H; Matos S; Manwani D; Green NS Contemp Clin Trials; 2016 Jul; 49():134-42. PubMed ID: 27327779 [TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists. Zumberg MS; Reddy S; Boyette RL; Schwartz RJ; Konrad TR; Lottenberg R Am J Hematol; 2005 Jun; 79(2):107-13. PubMed ID: 15929107 [TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision. Creary S; Zickmund S; Ross D; Krishnamurti L; Bogen DL BMC Res Notes; 2015 Aug; 8():372. PubMed ID: 26303306 [TBL] [Abstract][Full Text] [Related]
12. Improving Uptake of Hydroxyurea in Patients with Sickle Cell Disease: A Retrospective Study of a Clinic-based Change in Consenting Practices. Smith AW; Bodas P; Sidebotham L; Weilnau J; Wildman B J Natl Med Assoc; 2019 Apr; 111(2):169-175. PubMed ID: 30314826 [TBL] [Abstract][Full Text] [Related]
13. Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease. Haywood C; Beach MC; Bediako S; Carroll CP; Lattimer L; Jarrett D; Lanzkron S Am J Hematol; 2011 Jan; 86(1):85-7. PubMed ID: 21117058 [TBL] [Abstract][Full Text] [Related]
14. Higher nocturnal and awake oxygen saturations in children with sickle cell disease receiving hydroxyurea therapy. Narang I; Kadmon G; Lai D; Dhanju S; Kirby-Allen M; Odame I; Amin R; Lu Z; Al-Saleh S Ann Am Thorac Soc; 2015 Jul; 12(7):1044-9. PubMed ID: 25970812 [TBL] [Abstract][Full Text] [Related]
15. Higher oxygen saturation with hydroxyurea in paediatric sickle cell disease. van Geyzel L; Arigliani M; Inusa B; Singh B; Kozlowska W; Chakravorty S; Bossley CJ; Ruiz G; Rees D; Gupta A Arch Dis Child; 2020 Jun; 105(6):575-579. PubMed ID: 31871045 [TBL] [Abstract][Full Text] [Related]
16. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease. Creary SE; Gladwin MT; Byrne M; Hildesheim M; Krishnamurti L Pediatr Blood Cancer; 2014 Jun; 61(6):1068-73. PubMed ID: 24436121 [TBL] [Abstract][Full Text] [Related]
17. From trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea. Sinha CB; Bakshi N; Ross D; Krishnamurti L PLoS One; 2018; 13(6):e0199375. PubMed ID: 29949647 [TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148 [TBL] [Abstract][Full Text] [Related]